I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

John Purpura Biography and Net Worth

COO of Delcath Systems

Mr. Purpura joined the Company as Executive Vice President, Regulatory Affairs and Quality Assurance in November 2009 and was promoted to Executive Vice President, Global Head of Operations on July 19, 2016. He also served as Interim Chief Executive Officer of the Company from June 1, 2020 to October 1, 2020. Prior to joining the Company, he was with Bracco Diagnostics (formerly E-Z-EM,Inc.) as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008 and Head of Regulatory Affairs for North America and Latin America from 2008 to 2009. Prior to E-Z-EM, Inc., Mr. Purpura had an 11-year career with Sanofi-Aventis, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. From 1985 to 1995, he had various quality and regulatory management roles with Bolar Pharmaceuticals, Luitpold Pharmaceuticals and Eon Labs Manufacturing. He earned his M.S. in Management & Policy and B.S. degrees in Chemistry and Biology at the State University of New York at Stony Brook.

What is John Purpura's net worth?: The estimated net worth of John Purpura is at least $496,235.70 as of October 13th, 2023. Mr. Purpura owns 41,526 shares of Delcath Systems stock worth more than $496,236 as of December 3rd. This net worth estimate does not reflect any other investments that Mr. Purpura may own. Learn More about John Purpura's net worth.
How do I contact John Purpura?: The corporate mailing address for Mr. Purpura and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected]. Learn More on John Purpura's contact information.
Has John Purpura been buying or selling shares of Delcath Systems?: John Purpura has not been actively trading shares of Delcath Systems in the last ninety days. Most recently, on Friday, October 13th, John Purpura bought 14,505 shares of Delcath Systems stock. The stock was acquired at an average cost of $3.44 per share, with a total value of $49,897.20. Following the completion of the transaction, the chief operating officer now directly owns 41,526 shares of the company's stock, valued at $142,849.44. Learn More on John Purpura's trading history.
Who are Delcath Systems' active insiders?: Delcath Systems' insider roster includes Gerard Michel (CEO), John Purpura (COO), and Steven Salamon (Director). Learn More on Delcath Systems' active insiders.
Are insiders buying or selling shares of Delcath Systems?: During the last twelve months, Delcath Systems insiders bought shares 2 times. They purchased a total of 60,882 shares worth more than $199,961.04. The most recent insider tranaction occured on March, 19th when Director Gil Aharon bought 26,882 shares worth more than $100,001.04. Insiders at Delcath Systems own 17.9% of the company. Learn More about insider trades at Delcath Systems.
Information on this page was last updated on 3/19/2024.

John Purpura Insider Trading History at Delcath Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/13/2023	Buy	14,505	$3.44	$49,897.20	41,526
5/16/2022	Buy	3,300	$4.61	$15,213.00	27,021
4/11/2022	Buy	5,000	$6.59	$32,950.00	23,721
5/13/2021	Buy	4,000	$9.42	$37,680.00	18,713
9/28/2018	Buy	5,500	$1.75	$9,625.00

John Purpura Buying and Selling Activity at Delcath Systems

Delcath Systems Company Overview

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Today's Range

Now: $11.95

$11.68

$12.62

50 Day Range

MA: $9.87

$8.18

$11.88

2 Week Range

Now: $11.95

$2.60

$12.88

Volume

184,875 shs

Average Volume

283,377 shs

Market Capitalization

$382.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

I was wrong. Dead wrong.

From Porter & Company | Ad